An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
Improvements in all HRQoL measures from the end of ADVANCE IV were observed in both the efgartigimod treatment or cross-over to efgartigimod groups of the study. Patients with primary immune ...
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results